Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARISEL: Implementation of Long-Acting Cabotegravir + Rilpivirine in Europe
NCT04399551Phase 3Completed
- Sponsor
- ViiV Healthcare
- Start
- Sep 2020
- Primary completion
- Mar 2022
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of cabotegravir and rilpivirine in human immunodeficiency virus type 1 infection (HIV-1) (3 arms), sponsored by ViiV Healthcare. Primary endpoints: Acceptability of Implementation Measure at Month 12, Implementation Appropriateness Measure at Month 12 and 1 more. Started Sep 2020; status: completed.
02
Drugs
cabotegravirrilpivirine
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT04399551.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04399551.